HT3 Development of a Check List for Quality Assessment of Pharmacoeconomic Evaluations Submitted for Reimbursement in Taiwan  by Wu, G.H.M. et al.
health policy issues. The effects of each policy category were disentangled into
Price, Volume and Quality; and where an effect was identifiable, by comparing to
the intent of the policy, it was qualified by 3 sets of parameters: Direct-or-Indirect
Effect, Desired-or-Undesired Effect and Decreasing-or-Increasing Effect. RESULTS:
The identified 10 policies were grouped into 5 main categories: Essential Drug
Listing & Price Control (3), Essential Drug Usage Promotion (2), Reimbursed Drug
Listing & Price Control (2), Hospital Drug Price Controls (2), and Prescribing-Dis-
pensing Separation (1). The majority (4/5) of the policy categories were targeted
directly at lowering drug prices, and did achieve certain Direct-Desired-Decreasing
effects on Price. Three of these four policy categories, however, also had indirect-
undesired effects, mainly manifested as encouraging over-prescribing or lowering
drug quality. The other policy aimed at promoting rational pharmaceutical pre-
scribing failed to make tangible impact at national level. CONCLUSIONS: The drug
policies implemented during 2009-2011 achieved limited success and new ap-
proaches towards reform will be needed to obtain better results.
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OBJECTIVES: To investigate recent trends in reimbursement payment for phar-
macy service and pharmaceuticals from the Korean National Health Insurance
(NHI) using the NHI claims database. METHODS: Pharmacy claims data were ex-
tracted from the Korean NHI database from January 1, 2008 to March 31, 2011 by
quarterly unit. The monthly number of prescriptions of each pharmacy, the aver-
age number of supply-days per prescription, and payment amount to each phar-
macy including cost of pharmaceuticals and dispensing fees were calculated from
the claims. The information of all community pharmacies such as the number of
pharmacists in practice and pharmacy locationwas collected. The trends and vari-
ation in the pharmacy payment amount and the composition were traced on quar-
terly basis. RESULTS: Total claims of 15,996 pharmacies were included for analysis.
The monthly reimbursed payment per pharmacy increased from 29.73 million
Korean Won (KW) in 1Q 2008 to 36.41 million KW in 1Q 2011. While the increase
related to dispensing fees was 1.73 million KW per pharmacy for this period, the
amount contributing to pharmaceuticals increased from4.95million KW. The daily
number of prescriptions per pharmacist was ranged from 39.41 in 2008/3Q to 51.09
in 2009/4Q, which is below the current daily threshold for the discount of dispens-
ing fee in South Korea, 75 prescriptions per pharmacist. The average number of
supply-days per prescription was ranged from 9.12 in 2008/1Q to 11.32 in 2010/3Q.
CONCLUSIONS: While the number of prescriptions per pharmacist and supply-
days of prescriptions were relatively stable, the reimbursement amount per phar-
macy showed an increasing trend. The main source of the increase seemed to be
the payment for pharmaceuticals rather than pharmacy services.
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OBJECTIVES: The aim of this study was to compare the cost effectiveness of BMD-
(Bone Mineral Density) screening tools- RA, QUS, pDXA, QCT, and DXA, for wom-
en’s lifetime bone densitometry exam at 66 years old. METHODS: A total of 101
subjects aged in 60s’ were recruited to estimate sensitivity and specificity of each
BMD screening tool. A Markov model was developed to analyze the cost-effective-
ness of DXA, QUS, RA, pDXA, and QCT. A cohort of 10,000 women aged 66 was
constructed for each bone densitometry and a cohort of 10,000women aged 66was
also constructed as a non-exam group. In theMarkovmodel of osteoporosis and its
related fractures, costs and effectiveness measured by QALY were estimated until
the cohorts reached 100 years old or died. It was assumed that only costs were
discounted by 5% and the compliance for osteoporosis drugs was 38%. Sensitivity
analysis was performed on the discount rate and the compliance to osteoporosis
drugs. RESULTS: ICER (incremental cost-effectiveness ratio) is an indicator of how
much extra costs are needed to increase an extra 1QALY compared to the reference
group. The magnitudes of ICER’s were ordered as DXApDXA(QCT, RA, QUS).
DXA and pDXA cost extra 398,618 won and 453,947 won, respectively, in order to
increase 1 extra QALY compared to the non-exam group, which meant that DXA
and pDXA were very cost-effective. The extra costs for QUS, RA, and QCT to in-
crease 1 QALY compared to the non-exam group ranged 530,000 won‘590,000 won,
which meant that these were also cost-effective. CONCLUSIONS: All the BMD
screening tools that were examined in this study were found to be cost-effective in
terms of ICER. When the relative cost-effectiveness of pDXA, QUS, RA, and QCT
compared with DXA, DXA was predominant over the other.
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OBJECTIVES: It is not mandatory for pharmaceutical manufacturers to submit
cost-effectiveness evidence yet in Taiwan, but an incentive of a maximum 10%
mark-up for conducting local cost-effectiveness analysis has been announced
since 2010. HTA/CDE (Division of Health Technology Assessment, Center for Drug
Evaluation) assists the assessment on the strength of evidence of local cost-effec-
tiveness evaluation, and a checklist was therefore developed to ensure the consis-
tency and to improve the transparency. This study presents the impact of local
pharmacoeconomic incentive and the development of the checklist.METHODS: By
reviewing other international checklists for quality assessment of pharmacoeco-
nomic evidence and adding items for local adaptation and transferability, a check-
list consisting of four dimensions including PICOS, cost-effectiveness analysis de-
sign, source of parameters, and overall quality was developed with a four-level-
grading for evidence strength. The local pharmacoeconomic evidence was
identified from the dossiers submitted by themanufacturers during 2008-2011, and
was independently assessed by the four reviewers in the economic evaluation
team of HTA/CDE as reference cases. Discrepancies between reviewers were dis-
cussed until consensus was reached. RESULTS: There were 83 and 67 dossiers
submitted for reimbursement before and after the incentive was announced, re-
spectively. However, no local pharmacoeconomic evidence has been submitted
until eight months after the incentive was announceed. Another four dossiers
consist of five local pharmacoeconomic evaluation (one with multiple indications)
were submitted in 2011. The strengths of evidencewere graded as strong,medium,
low, and very low for 0, 1, 2, and 3 cases according to the checklist. CONCLUSIONS:
A pragmatic strategy was used to incorporate cost-effectiveness evidence into the
drug reimbursement decisions in Taiwan. Local pharmacoeconomic evidence sub-
missions increase slowly after the incentive was announced. A quality assessment
checklist was proposed. Further experience will be cumulated and discussed
among the submitting bodies, the appraisal committee members, and HTA/CDE.
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OBJECTIVES: To gain insights into health technology assessments (HTA) landscape
in Asia and to better understand international influence dynamics across intercon-
nected HTA universe. METHODS: Information on major Asian HTA agencies
(NECA, HITAP, CDE, etc) was collected and analysed at the level of four data cate-
gories: agencies, institutions, people (members) and assessments. For each cate-
gory a number of attributes were included (such as location, affiliations, member-
ships, type of technology, decision on technology). The Ni3 softwarewas applied to
add multiple types of connections between the datasets to conduct the analysis
and visualize HTA networks. The tool enabled mapping of relationship links that
represent direction and weight of influence, overlaying displayed stakeholders
with visual charts summarizing sets of quantitative values (such as number of
employees or budget) for visual patternmatching and comparison, and geographic
analysis. RESULTS: The analysis revealed the initiated collaboration between HTA
stakeholders in the Asia region. In the centre of the Asian HTA ecosystem are
located the most established agencies in Korea, Taiwan and Thailand where HTA
already yields important evidence to inform policy and practice. The visual analy-
sis revealed patterns of collaboration where agencies were 1) referring to each
other; 2) referring to the same sources and academic institutions, and 3) absorbing
the experience from well-established European HTA agencies such as NICE or
IQWIG. CONCLUSIONS: HTA has expanded globally and can be characterised by
common patterns in interactions when looking at and refining the evidence re-
quired for the reimbursment. Rapidly growing in number and in influence HTA
organizations in Asia are strengthening their abilities through collaboration with
each other, by involving independent research institutions into the HTA process
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OBJECTIVES: To evaluate the association between medication adherence and
Health Related Quality of Life (HRQoL) among hypertension patients in Quetta city,
Pakistan. METHODS: A questionnaire based cross sectional study design was un-
dertakenwith hypertension patients attending public hospitals in Quetta city, Pak-
istan. HRQoLwasmeasured by Euroqol EQ-5D.Medication adherencewas assessed
by Drug Attitude Inventory. Descriptive statistics was used to tabulate demo-
graphic and disease related information. Spearman’s correlation was used to as-
sess the association between the study variables. All analysis was performed by
using SPSS 17.0. RESULTS: Among 385 study patients, mean age (SD) was 39.02
(6.59), with 68.8% of males dominating the entire cohort. Mean (SD) duration of
hypertension was 3.010.939 years. Forty percent (n154) had bachelor level of
education with 34.8% (n134) working in the private sector. Negative and weak
correlation (-0.77) between medication adherence and EQ-5D was reported. In ad-
dition, negative week but significant correlation (-0.120, p0.019) was observed
among medication adherence and EQ-VAS. CONCLUSIONS: No apparent relation-
ship between medication adherence and HRQoL was reported. Improved medica-
tion adherence therefore in patients with hypertension does not necessarily im-
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